202 related articles for article (PubMed ID: 34718134)
1. Therapeutic potential of targeting LSD1/ KDM1A in cancers.
Zhang X; Wang X; Wu T; Yin W; Yan J; Sun Y; Zhao D
Pharmacol Res; 2022 Jan; 175():105958. PubMed ID: 34718134
[TBL] [Abstract][Full Text] [Related]
2. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
4. Annual review of LSD1/KDM1A inhibitors in 2020.
Fu DJ; Li J; Yu B
Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
[TBL] [Abstract][Full Text] [Related]
5. Advances toward LSD1 inhibitors for cancer therapy.
Fu X; Zhang P; Yu B
Future Med Chem; 2017 Jul; 9(11):1227-1242. PubMed ID: 28722477
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Inhibition of LSD1 for Cancer Treatment.
Yang GJ; Lei PM; Wong SY; Ma DL; Leung CH
Molecules; 2018 Dec; 23(12):. PubMed ID: 30518104
[TBL] [Abstract][Full Text] [Related]
7. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
8. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
[TBL] [Abstract][Full Text] [Related]
9. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
Fang Y; Liao G; Yu B
J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
[TBL] [Abstract][Full Text] [Related]
10. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
11. Research progress of LSD1-based dual-target agents for cancer therapy.
Yang X
Bioorg Med Chem; 2024 Mar; 101():117651. PubMed ID: 38401457
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
13. LSD1: biologic roles and therapeutic targeting.
Maiques-Diaz A; Somervaille TC
Epigenomics; 2016 Aug; 8(8):1103-16. PubMed ID: 27479862
[TBL] [Abstract][Full Text] [Related]
14. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
Song Y; Zhang H; Yang X; Shi Y; Yu B
Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
[TBL] [Abstract][Full Text] [Related]
15. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.
Wang J; Lu F; Ren Q; Sun H; Xu Z; Lan R; Liu Y; Ward D; Quan J; Ye T; Zhang H
Cancer Res; 2011 Dec; 71(23):7238-49. PubMed ID: 21975933
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
17. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
[TBL] [Abstract][Full Text] [Related]
18. ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway.
Li Y; Tao L; Zuo Z; Zhou Y; Qian X; Lin Y; Jie H; Liu C; Li Z; Zhang H; Zhang H; Cen X; Yang S; Zhao Y
Cancer Lett; 2019 Jul; 454():179-190. PubMed ID: 30978443
[TBL] [Abstract][Full Text] [Related]
19. LSD1 inhibition: a therapeutic strategy in cancer?
Lynch JT; Harris WJ; Somervaille TC
Expert Opin Ther Targets; 2012 Dec; 16(12):1239-49. PubMed ID: 22957941
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
